SYNLAB offers a full range of medical laboratory services for practising doctors, clinics and patients. The SYNLAB Group is the uncontested leader on the European market for human medicine laboratory services.
We provide fast, reliable, high-quality diagnostic services in 36 countries across 4 continents.
We provide fast, reliable, high-quality diagnostic services in 36 countries across 4 continents.
Location: Germany, Bavaria, Munich
Employees: 10001+
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | Cinven | cinven.com |
Mentions in press and media 23
| Date | Title | Description |
| 13.05.2026 | Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. | LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing ... |
| 12.11.2025 | Synnovis Updates On Data Breach From 2024 Ransomware Attack | Synnovis, the UK pathology service provider which faced a ransomware attack in June 2024 is now notifying healthcare providers of the data breach and patient data theft that resulted from the attack. The London-based provider has partnershi... |
| 10.10.2025 | 7 African startups transforming health records, human resource, and home care | Startups On Our Radar spotlights African startups solving African challenges with innovation. In our previous edition, we featured seven game-changing startups pioneering health, artificial intelligence, commerce, and mobility. Expect the n... |
| 22.08.2024 | Nadmed Raises €3.5M in Series A Funding | Nadmed, a Helsinki, Finland-based biotech company developing a testing method to measure all four NADs*, raised €3.5M in Series A funding. The round was led by Nordic Science Investments (NSI) with participation from previous investors Voim... |
| 22.08.2024 | Finnish biotech NADMED raises €3.5 million Series A for vitamin B3 deficiencies testing | Helnsinki-based NADMED has closed a €3.5 million series A round to fund its entry to the U.S. and other international markets with its proprietary nicotinamide adenine dinucleotide (NAD) measurement technology that may help clinicians estab... |
| 22.08.2024 | NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options | NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options Thu, Aug 22, 2024 10:30 CET Report this content Finnish biotech company NADMED has developed the first test to measure all four bodily... |
| 17.06.2024 | InnoStars Connect health innovation program applications are now open | Startups, researchers from small and medium-sized enterprises (SMEs), universities, and hospitals in Latvia are invited to apply to InnoStars Connect, a challenge-based program for emerging European countries, by June 30th. This program pro... |
| 07.11.2023 | Antech launches first comprehensive veterinary diagnostics offering in the UK, including a new state-of-the-art reference laboratory | Antech to offer UK veterinary professionals a complete and flexible diagnostics portfolio spanning reference labs, in-house diagnostics, imaging and software WARWICK, England, 7 Nov. 2023 /PRNewswire/ -- Antech, the full-service veterinary ... |
| 07.01.2022 | SYNLAB acquires Sistemas Genómicos of the Ascires Group in Spain, further strengthening its European leadership in genetics | DGAP-News: SYNLAB AG / Key word(s): Acquisition SYNLAB acquires Sistemas Genómicos of the Ascires Group in Spain, further strengthening its European leadership in genetics 07.01.2022 / 08:00 The issuer is solely responsible for the content ... |
| 10.11.2021 | SYNLAB delivers strong 9M 2021 results, on track to significantly exceed 2021 financial targets set at IPO | DGAP-News: SYNLAB AG / Key word(s): Quarter Results SYNLAB delivers strong 9M 2021 results, on track to significantly exceed 2021 financial targets set at IPO 10.11.2021 / 07:29 The issuer is solely responsible for the content of this annou... |
Show more